The latest update is out from Aceso Life Science Group Limited ( (HK:0474) ).
Aceso Life Science Group Limited announced the formation of a joint venture with Jiangsu Lettall, with HTICI, a subsidiary of Aceso, holding a 75% stake. This joint venture will become a subsidiary of Aceso, consolidating its financial results with the group. The transaction is considered a major one under the Hong Kong Listing Rules, requiring shareholder approval, which has been obtained from a group controlling over 57% of the company’s shares. The venture aims to strengthen Aceso’s market position and expand its operational scope.
More about Aceso Life Science Group Limited
Aceso Life Science Group Limited operates in the life sciences industry, focusing on the development and management of health-related technologies and services. The company is involved in forming strategic partnerships to enhance its market presence and operational capabilities.
YTD Price Performance: 2.00%
Average Trading Volume: 268,464
Technical Sentiment Signal: Buy
Current Market Cap: HK$376.5M
For detailed information about 0474 stock, go to TipRanks’ Stock Analysis page.